A neoantigen cancer immunotherapy has been developed by Dr. Mark Mamula and Yale University investigators. The neoantigen targets EGFR/HER2 overexpressing cancers, including lung cancer, breast cancer, colon and brain cancer, prostate and ovarian cancers, among others. The therapeutic immunization is presently in clinical trials in canine cancer and awaiting licensing by the USDA as a veterinary cancer biologic. Pre-clinical studies will be performed in primates to support therapeutic efficacy in human clinical trials. Intellectual property for human and canine use issued to Yale University.